Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by KAI CAO and RICHARD E CHAMPLIN.
KAI CAO
Connection Strength
2.914
RICHARD E CHAMPLIN
  1. Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer. 2023 04 15; 129(8):1205-1216.
    View in: PubMed
    Score: 0.220
  2. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther. 2023 03; 29(3):189-198.
    View in: PubMed
    Score: 0.217
  3. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol. 2022; 13:1033871.
    View in: PubMed
    Score: 0.215
  4. Correction to: Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 Jan; 36(1):298.
    View in: PubMed
    Score: 0.204
  5. Treatment of allosensitized patients receiving allogeneic transplantation. Blood Adv. 2021 10 26; 5(20):4031-4043.
    View in: PubMed
    Score: 0.201
  6. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 01; 36(1):155-164.
    View in: PubMed
    Score: 0.198
  7. Donor clonal hematopoiesis increases risk of acute graft versus host disease after matched sibling transplantation. Leukemia. 2022 01; 36(1):257-262.
    View in: PubMed
    Score: 0.196
  8. Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation. Blood Adv. 2020 08 11; 4(15):3474-3485.
    View in: PubMed
    Score: 0.185
  9. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol. 2018; 9:2444.
    View in: PubMed
    Score: 0.163
  10. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.
    View in: PubMed
    Score: 0.151
  11. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017 10 19; 130(16):1857-1868.
    View in: PubMed
    Score: 0.151
  12. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant. 2016 07; 22(7):1290-1298.
    View in: PubMed
    Score: 0.137
  13. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70.
    View in: PubMed
    Score: 0.131
  14. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial. Nat Med. 2024 Mar; 30(3):772-784.
    View in: PubMed
    Score: 0.059
  15. SIRPa Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol. 2022; 13:904718.
    View in: PubMed
    Score: 0.053
  16. Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica. 2022 04 01; 107(4):844-856.
    View in: PubMed
    Score: 0.052
  17. Mismatch in SIRPa, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv. 2021 09 14; 5(17):3407-3417.
    View in: PubMed
    Score: 0.050
  18. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020 02 06; 382(6):545-553.
    View in: PubMed
    Score: 0.045
  19. Is a matched unrelated donor search needed for all allogeneic transplant candidates? Blood Adv. 2018 09 11; 2(17):2254-2261.
    View in: PubMed
    Score: 0.040
  20. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.
    View in: PubMed
    Score: 0.039
  21. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation after Reduced-Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1359-1366.
    View in: PubMed
    Score: 0.037
  22. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
    View in: PubMed
    Score: 0.036
  23. KIR gene haplotype: an independent predictor of clinical outcome in MDS patients. Blood. 2016 12 15; 128(24):2819-2823.
    View in: PubMed
    Score: 0.035
  24. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.
    View in: PubMed
    Score: 0.035
  25. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016 07 14; 128(2):297-312.
    View in: PubMed
    Score: 0.035
  26. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1392-8.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.